nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.06.2012 | Review Article

Lenalidomide in solid tumors

verfasst von: Angela Segler, Apostolia-Maria Tsimberidou

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Lenalidomide is a thalidomide analogue with immunomodulatory and anti-angiogenic properties that include altering cytokine production, activating T cells, and augmenting natural killer cell function. Lenalidomide is approved by the U.S. Food and Drug Administration (FDA) for single-agent treatment of myelodysplastic syndromes associated with a 5q deletion and as a combination therapy with dexamethasone for the treatment of multiple myeloma.

Methods

All prospective phase I–III clinical trials and preclinical data published until October 2011 and relevant literature were reviewed.

Results

In phase I and/or II studies of single-agent lenalidomide in patients with advanced cancer, responses were reported in patients with prostate, thyroid, hepatocellular, pancreatic, and renal cancer and melanoma. The most common toxicities were hematologic, and in the first clinical trials, thrombotic events were noted. When anticoagulation prophylaxis and exclusion of patients with a history of thrombosis were implemented, thrombotic complications became uncommon.

Conclusion

Monitoring of blood counts and for evidence of thromboembolic events is essential for patients treated with lenalidomide. Ongoing trials of lenalidomide combination therapy offer a treatment option for patients with advanced cancer and will better define the role of lenalidomide in solid tumors.

Knight R (2005) IMiDs: a novel class of immunomodulators. Semin Oncol 32(4 Suppl 5):S24–S30. doi:10.1053/j.seminoncol.2005.06.018 PubMedCrossRef

Tohnya TM, Hwang K, Lepper ER, Fine HA, Dahut WL, Venitz J, Sparreboom A, Figg WD (2004) Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 811(2):135–141. doi:10.1016/j.jchromb.2004.08.022 PubMed

Muller GW, Chen R, Huang SY, Corral LG, Wong LM, Patterson RT, Chen Y, Kaplan G, Stirling DI (1999) Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 9(11):1625–1630PubMedCrossRef

Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380–386PubMed

Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177(6):1675–1680PubMedCrossRef

Melchert M, List A (2007) The thalidomide saga. Int J Biochem Cell Biol 39(7–8):1489–1499. doi:10.1016/j.biocel.2007.01.022 PubMedCrossRef

Stirling D (2001) Thalidomide: a novel template for anticancer drugs. Semin Oncol 28(6):602–606PubMedCrossRef

Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG (2002) Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 130(1):75–84PubMedCrossRef

Sharpe AH, Abbas AK (2006) T-cell costimulation–biology, therapeutic potential, and challenges. N Engl J Med 355(10):973–975. doi:10.1056/NEJMp068087 PubMedCrossRef

10.

LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NC (2004) Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103(5):1787–1790. doi:10.1182/blood-2003-02-0361 PubMedCrossRef

11.

Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI, Dalgleish AG (2002) Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 168(10):4914–4919PubMed

12.

Haslett PA, Corral LG, Albert M, Kaplan G (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187(11):1885–1892PubMedCrossRef

13.

Teo SK (2005) Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 7(1):E14–E19. doi:10.1208/aapsj070103 PubMedCrossRef

14.

Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A (2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2:36. doi:10.1186/1756-8722-2-36 PubMedCrossRef

15.

Wu L, Adams M, Parton S, Lu L, Schafer P, Bartlett JB, Celgene Corporation S, NJ (2010) Influence of NKG2D/DNAM-1 interaction with tumor cell ligands on the ability of lenalidomide to enhance ADCC of antibody-coated solid tumor cells. In: ASCO annual meeting, Chicago, IL, J Clin Oncol 28(suppl; abstr e21008)

16.

Bartlett JB, Wu L, Adams M, Schafer P, Muller G, Stirling D (2007) Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab. In: ASCO annual meeting, J Clin Oncol 25(18S, Part I):123s, Abstract #3023

17.

Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB (2011) Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother 60(1):61–73. doi:10.1007/s00262-010-0919-9 PubMedCrossRef

18.

Blagosklonny MV (2004) Antiangiogenic therapy and tumor progression. Cancer Cell 5(1):13–17PubMedCrossRef

19.

Harris AL (2002) Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38–47. doi:10.1038/nrc704 PubMedCrossRef

20.

Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441(7092):437–443. doi:10.1038/nature04871 PubMedCrossRef

21.

Lu L, Schafer P, Bartlett JB, Celgene Corporation, Summit, NJ (2010) Effect of lenalidomide on hypoxia-induced HIF-1α signaling and the invasive phenotype in epithelial solid tumor cells. In: ASCO Annual Meeting Chicago, IL, J Clin Oncol

22.

Liao D, Corle C, Seagroves TN, Johnson RS (2007) Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67(2):563–572. doi:10.1158/0008-5472.CAN-06-2701 PubMedCrossRef

23.

Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69(1–2):56–63. doi:10.1016/j.mvr.2005.01.002 PubMedCrossRef

24.

Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15(12):1950–1961PubMedCrossRef

25.

Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CCW, Stirling DI, Schafer PH, Bartlett JB (2009) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77(2):78–86. doi:10.1016/j.mvr.2008.08.003 PubMedCrossRef

26.

Kataoka N, Iwaki K, Hashimoto K, Mochizuki S, Ogasawara Y, Sato M, Tsujioka K, Kajiya F (2002) Measurements of endothelial cell-to-cell and cell-to-substrate gaps and micromechanical properties of endothelial cells during monocyte adhesion. Proc Natl Acad Sci U S A 99(24):15638–15643. doi:10.1073/pnas.242590799 PubMedCrossRef

27.

Lin MT, Yen ML, Lin CY, Kuo ML (2003) Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol 64(5):1029–1036. doi:10.1124/mol.64.5.1029 PubMedCrossRef

28.

Matsumura T, Wolff K, Petzelbauer P (1997) Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin. J Immunol 158(7):3408–3416PubMed

29.

Osaki M, Oshimura M, Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9(6):667–676. doi:10.1023/B:APPT.0000045801.15585.dd PubMedCrossRef

30.

Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI (2006) Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 30(7):849–858. doi:10.1016/j.leukres.2006.01.010 PubMedCrossRef

31.

Tohnya T, Gulley J, Arlene P, Sparreboom A, Venitz J, Parker C, Fedenko K, Parnes H, Figg WD, Weber D (2006) Phase I study of lenalidomide, a novel thalidomide analog, in patients with refractory metastatic cancer, J Clin Oncol. ASCO annual meeting proceedings 24(18s, Part 1): 605s, Abstract # 13038

32.

Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI, Zeldis J, Dalgleish AG (2004) Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 90(5):955–961. doi:10.1038/sj.bjc.6601579 PubMedCrossRef

33.

Sharma RA, Steward WP, Daines CA, Knight RD, O’Byrne KJ, Dalgleish AG (2006) Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer 42(14):2318–2325. doi:10.1016/j.ejca.2006.05.018 PubMedCrossRef

34.

Glaspy J, Atkins MB, Richards JM, Agarwala SS, O’Day S, Knight RD, Jungnelius JU, Bedikian AY (2009) Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer 115(22):5228–5236. doi:10.1002/cncr.24576 PubMedCrossRef

35.

Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, Jungnelius JU, Glaspy J (2010) Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer 116(1):146–154. doi:10.1002/cncr.24686 PubMed

36.

Hwu WJ, Knight RD, Patnana M, Bassett R, Papadopoulos NE, Kim KB, Hwu P, Bedikian A (2010) Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. Melanoma Res 20(6):501–506. doi:10.1097/CMR.0b013e32833faf18 PubMedCrossRef

37.

Sanborn SL, Gibbons J, Krishnamurthi S, Brell JM, Dowlati A, Bokar JA, Nock C, Horvath N, Bako J, Remick SC, Cooney MM (2009) Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Invest New Drugs 27(5):453–460. doi:10.1007/s10637-008-9200-x PubMedCrossRef

38.

Papadopoulos KMD, Preston GG, Lopez AM, Ricart AD, Schwartz G, Needle MN, Gordon MS (2005) A Phase I study of lenalidomide and weekly docetaxel in patients with advaced solid tumors. In: Proceedings of the AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics, vol 11, no 24 Pt 2, p 215, Abstract #C71

39.

Ain K, Lee C, Holbrook KM, Dziba JM, Williams KD (2008) Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine- unresponsive thyroid carcinomas: preliminary results. In: ASCO annual meeting, Chicago, IL, J Clin Oncol 26(May 20 suppl; abstr 6027)

40.

Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA (2007) Phase I study of lenalidomide in solid tumors. J Thorac Oncol 2(5):445–449. doi:10.1097/01.JTO.0000268679.33238.67 PubMedCrossRef

41.

Arkenau H, Infante JR, Bendell JC, Burris HA, Rubin MS, Waterhouse DM, Jones GT, Spigel DR (2011) Lenalidomide in combination with gemcitabine in patients with untreated metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial. In: ASCO annual meeting, J Clin Oncol 29(suppl; abstr e14640)

42.

Liu WM, Nizar S, Dalgleish AG (2010) Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study. Med Oncol 27(2):430–433. doi:10.1007/s12032-009-9228-6 PubMedCrossRef

43.

Zhang MM, Chan JK, Husain A, Guo HY, Teng NN (2007) Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma. Gynecol Oncol 105(1):194–198. doi:10.1016/j.ygyno.2006.11.026 PubMedCrossRef

44.

Carter JS, Downs LS Jr (2011) A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma. Int J Clin Oncol. doi:10.1007/s10147-011-0243-1 PubMed

45.

Carter JS, Geller M, Judson P, Argenta P, Ghebre R, Jonson A, Carson L, Downs L (2011) A phase I study of lenalidomide in combination with liposomal doxorubicin in recurrent epithelial ovarian cancer. In: Proceedings of the 47th annual meeting of ASCO, Chicago, IL, J Clin Oncol 29(suppl; abstr e15545)

46.

Sanborn SL, Cooney M, Gibbons J, Bokar JA, Nock CJ, Bako J, Horvath N, Tirgan NJ, Remick S (2008) Phase I trial of docetaxel given every three weeks and daily lenalidomide in patients with advanced solid tumors. Genitourinary cancers symposium abstract#183

47.

Safran H, Charpentier K, Kaubisch A, Dubel G, Soares G, Faricy-Anderson KE, Miner TJ, Eng Y, Ribizzi-Akhtar I, Plette AM, Espat NJ, Berz D, Schumacher A, Luppe D, Bakalarski P, Wingate P, Victor J, Rosati K (2010) Lenalidomide for advanced hepatocellular cancer (HCC) in patients progressing on or intolerant to sorafenib. In: ASCO annual meeting, J Clin Oncol 28

48.

Schilling G, Schuch G, Panse JP, Sterneck M, Bokemeyer C (2009) Activity of lenalidomide in metastatic hepatic epithelioid hemangioendothelioma (HEH): a case report. ASCO annual meeting (suppl; abstr e21527)

49.

Henry JY, Lu L, Adams M, Meyer B, Bartlett JB, Dalgleish AG, Galustian C (2011) Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Prostate. doi:10.1002/pros.21488

50.

Zabransky DJ, Smith HA, Thoburn CJ, Zahurak M, Keizman D, Carducci M, Eisenberger MA, McNeel DG, Drake CG, Antonarakis ES (2011) Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate. doi:10.1002/pros.21449

51.

Dahut WL, Aragon-Ching JB, Woo S, Tohnya TM, Gulley JL, Arlen PM, Wright JJ, Ventiz J, Figg WD (2009) Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 49(6):650–660. doi:10.1177/0091270009335001 PubMedCrossRef

52.

Lestingi TM, Tolzien K, Kelby SK, Nabhan C (2010) Safety and activity of lenalidomide (LEN) in elderly patients (pts) with chemotherapy-naive, castration-resistant prostate cancer (CRPC). ASCO annual meeting, vol 28, no suppl; abstr e15125

53.

Petrylak DP, Resto-Garces K, Tibyan M, Mohile SG, Columbia University Medical Center NY, NY, University of Rochester R, NY (2009) A phase I open-label study using lenalidomide and docetaxel in castration—resistant prostate cancer. In: ASCO annual meeting, J Clin Oncol

54.

Mathew P, Tannir N, Tu SM, Carter CM, Bekele NB, Pagliaro L (2010) A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol 65(4):811–815. doi:10.1007/s00280-009-1237-9 PubMedCrossRef

55.

Garcia J, Triozzi P, Smith S, Rini B, Gilligan T, Peereboom D, Elson P, Klein E, Dreicer R (2007) Phase I/II study of lenalidomide and GM-CSF in hormone refractory prostate cancer (HRPC). Prostate cancer symposium abstract #229

56.

Garcia J, Triozzi P, Elson P, Cooney M, Tyler A, Gilligan T, Dreicer R (2008) Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma (CPPCA): preliminary results of a phase II trial. J Clin Oncol 26(May 20 suppl; abstr 5143)

57.

Huang X, Ning YM, Mulquin M, Madan RA, Gulley JL, Kluetz PG, Adelberg D, Arlen PM, Parnes HL, Adesunloye B, Steinberg SM, Wright JJ, Trepel JB, Chen C, Bassim C, Apolo AB, Figg WD, Dahut WL (2011) Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (poster). In: ASCO annual meeting, J Clin Oncol 29(suppl; abstr 4574)

58.

Amato RJ, Hernandez-McClain J, Saxena S, Khan M (2008) Lenalidomide therapy for metastatic renal cell carcinoma. Am J Clin Oncol 31(3):244–249. doi:10.1097/COC.0b013e31815e451f PubMedCrossRef

59.

Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM (2006) Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 107(11):2609–2616. doi:10.1002/cncr.22290 PubMedCrossRef

60.

Patel PH, Kondagunta GV, Schwartz L, Ishill N, Bacik J, DeLuca J, Russo P, Motzer RJ (2008) Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Invest New Drugs 26(3):273–276. doi:10.1007/s10637-007-9107-y PubMedCrossRef

61.

Mut M, Polar G, Carpenter JE, Redpath G, Larner J, Schiff D, Shaffrey ME (2007) Evaluation of lenalidomide activity on glioblastoma cell lines in vitro. J Neurol Sci 24(1):029–037

62.

Warren KE, Goldman S, Pollack IF, Fangusaro J, Schaiquevich P, Stewart CF, Wallace D, Blaney SM, Packer R, Macdonald T, Jakacki R, Boyett JM, Kun LE (2011) Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol 29(3):324–329. doi:10.1200/JCO.2010.31.3601 PubMedCrossRef

63.

Fine HA, Kim L, Albert PS, Duic JP, Ma H, Zhang W, Tohnya T, Figg WD, Royce C (2007) A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res 13(23):7101–7106. doi:10.1158/1078-0432.CCR-07-1546 PubMedCrossRef

64.

Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, Lafrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, Barron L, Sceppa C, Black PM, Wen PY (2009) A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 73(1):222–227. doi:10.1016/j.ijrobp.2008.03.046 PubMedCrossRef

65.

Kalmadi S, Davis M, Dowlati A, O’Keefe S, Cline-Burkhardt M, Pelley RJ, Borden E, Dreicer R, Bukowski R, Mekhail T (2007) Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors. Invest New Drugs 25(3):211–216. doi:10.1007/s10637-006-9025-4 PubMedCrossRef

66.

Shammo JM, Kassar M, Robin I, Knight R (2007) A case report of sarcoma regression in a patient with MDS treated with lenalidomide. In: ASCO annual meeting, J Clin Oncol

67.

Brosseau C, Colston K, Bartlet B, Dalgleish AG, Galustian C, St Georges University of London L, United Kingdom, Celgene Corporation S, NJ (2010) The immunomodulatory drug lenalidomide restores a Vitamin D sensitive phenotype to the Vitamin D resistant breast cancer cell line MDA-MB-231. In: Proceedings of the American Association for Cancer Research, Washington, DC

68.

Liu WM, Henry JY, Meyer B, Bartlett JB, Dalgleish AG, Galustian C (2009) Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer 101(5):803–812. doi:10.1038/sj.bjc.6605206 PubMedCrossRef

Titel: Lenalidomide in solid tumors
verfasst von: Angela Segler
Apostolia-Maria Tsimberidou
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 6/2012
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-012-1874-2

Springer Medizin

Lenalidomide in solid tumors

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2012

The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients

Ascorbic acid and healthy lymphocytes: a way to explain anticancer activity?

An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel

Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie